170 related articles for article (PubMed ID: 21684151)
1. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
3. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
[TBL] [Abstract][Full Text] [Related]
4. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
[TBL] [Abstract][Full Text] [Related]
6. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
7. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
12. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
17. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
[TBL] [Abstract][Full Text] [Related]
20. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
